Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | BTK | Q06187 | 1/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444276 | 1.00 | KDM4E (0.55) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL27177141 | 0.87 | BTK (0.52) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL30919617 | 0.87 | BTK (0.52) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL29967741 | 0.87 | BTK (0.52) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL27264433 | 0.84 | BTK (0.44) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL30919619 | 0.84 | BTK (0.44) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL30919628 | 0.83 | KDM4E (0.42) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL30919680 | 0.83 | BTK (0.46) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL27263103 | 0.83 | BTK (0.46) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 | |
| SCHEMBL30919867 | 0.82 | ALDH1A1 (0.43) | KDM4EALDH1A1HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148210-A1 | CYCLIN-DEPENDENT KINASE 12 MODULATORS AND THERAPEUTIC USES THEREOF | ALLIANTHERA (SUZHOU) BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | WO | disclosed |
| CN-117430589-A | 2-aminopyrimidine compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | WHAN IN PHARMACEUTICAL CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| CN-101309918-B | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI | 2010-12-29 | — | — | CN | disclosed |
| CN-101309918-A | [4-(benzo[b]thiophen-2-yl)-pyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases | LILLY CO ELI (US) | 2008-11-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219930-A1 | NOVEL PYRIMIDINE DERIVATIVE, AND COMPOSITION FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES AND CANCER, COMPRISING SAME | LRRK2, PARK7, SLC29A2 | KDM4E 2783/4885ALDH1A1 2108/4885HPGD 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.